-
Insulin market feels the speed and passion!
Time of Update: 2022-05-19
The terminal data of China's urban public hospitals, county-level public hospitals, urban community centers and township health centers shows that in 2020, Novo Nordisk alone will occupy about 46% of the domestic insulin and its analogs market, and Sanofi will occupy About 15%, Lilly accounted for about 11%, accounting for more than 70% of the market share in total, but after the implementation of national procurement, the pattern is about to change .
-
86 protected varieties of traditional Chinese medicine have captured the market of 17 billion!
Time of Update: 2022-05-19
Table 3: In the first half of 2021, the exclusive Chinese medicine protection variety with sales of over 100 million yuan in Chinese public medical institutions is Harbin Zhenbao Pharmaceutical's exclusive product Xueshuantong capsule, which has grown rapidly in recent years.
-
Over $10 billion in anticoagulants!
Time of Update: 2022-05-19
Because the drug is still in the patent protection period, currently only the original research product is on the market in the United States .
Since April, there have been frequent reports of good news from Huahai Pharmaceutical .
-
The 13-province alliance led by Henan is here!
Time of Update: 2022-05-19
Therefore, the Henan Provincial Medical Insurance Bureau requires: All medical institutions should adhere to seeking truth from facts, and reasonably fill in the pre-purchased volume of drugs based on the agreed procurement volume of the unit and the actual use of the previous procurement cycle .
-
5 Hong Kong and Macao traditional external Chinese patent medicines have been approved for listing in the mainland
Time of Update: 2022-05-19
In order to promote the integrated and innovative development of the Guangdong-Hong Kong-Macao Greater Bay Area and provide convenience for Hong Kong and Macao residents living and working in the Mainland, the Guangdong Provincial Drug Administration attaches great importance to simplifying the approval of traditional external Chinese patent medicines that have been marketed in Hong Kong and Macao to ensure that the standards of products marketed in the Mainland are not lowered and the quality is satisfactory.
-
Emergency, outpatient, medication... How about the medical treatment of patients outside of Shanghai's new crown?
Time of Update: 2022-05-17
The reporter learned from the Shanghai New Coronary Pneumonia Epidemic Prevention and Control Press Conference held on the 24th that compared with the beginning of April, the number of outpatient visits in 36 municipal hospitals recently increased by 103%, and the number of emergency departments increased by 65% .
-
Approved to join, follow the "seven unifications", the new method of Guangdong pharmaceutical retail chain is here!
Time of Update: 2022-05-17
On May 1, the "Guangdong Provincial Drug Retail Chain Management Supervision and Administration Measures" (referred to as the "Measures") issued by the Guangdong Provincial Drug Administration will b
-
The procurement data of immune analysis equipment in the first quarter of 2022 was announced, down nearly 60% year-on-year
Time of Update: 2022-05-17
Data source: JOINCHAIN® Ranking of Zhongcheng Digital Distributors According to the winning bid results, the distributor with the highest total sales in the first quarter of 2022 is Beijing Huazheng Boyan Technology Co.
-
The large variety of anti-gout was "cut in half", and 4 new drugs of class 1 of traditional Chinese medicine were strongly filled
Time of Update: 2022-05-17
Figure 1: Market size of chemical anti-gout preparations in recent years (unit: 100 million yuan) Source: Minet.
Table 1: Recently approved clinical anti-gout TCM class 1 new drugs Source: CDE official website Huzhen Qingfeng Capsule has become the first class 1 new TCM drug approved for the treatment of gout in China.
-
Qilu won the first imitation!
Time of Update: 2022-05-17
Among the domestic JAK inhibitors, only tofacitinib citrate tablets have been approved for generic drugs, and Hengrui, Kelun, Chia Tai Tianqing.
On April 21, the official website of the State Food and Drug Administration showed that Qilu Pharmaceutical's tofacitinib citrate sustained-release tablets were approved for marketing, becoming the first domestic imitation + first review .
-
The price of mixed nucleic acid testing in Shandong has been lowered again: the price standard of 4 yuan will be implemented from the 26th
Time of Update: 2022-05-17
In order to meet the requirements of the new coronavirus pneumonia epidemic prevention and control situation and reduce the burden on the public, on the basis of effectively reducing the price of nuc
-
Shandong new era strikes again!
Time of Update: 2022-05-17
Figure 1: Shandong New Era's product registration progress Source: NMPA official website Enoxaparin sodium injection is a low molecular weight heparin, mainly used for the treatment of symptoms such as anticoagulation and antithrombosis, and for the prevention and treatment of thrombosis or embolic diseases (such as myocardial infarction, thrombophlebitis, pulmonary embolism, etc.
-
National Medical Insurance Bureau: In-hospital marketing model of consumables has completely changed
Time of Update: 2022-05-17
Both of these reforms promote the transformation of the operating mechanism of medical institutions through the method of package pricing, prompting medical service providers to actively control costs, reduce unnecessary diagnosis and treatment, medicine and consumables items, and improve the level of refined management .
-
The State Food and Drug Administration has approved 29 new coronavirus antigen detection reagents
Time of Update: 2022-05-17
On April 20, the State Food and Drug Administration reviewed and approved two new coronavirus antigen detection reagent products again .
As of April 20, the State Food and Drug Administration has approved 29 new coronavirus antigen detection reagent products .
-
5 kinds of the world's first batch of new drugs approved by PMDA in the first quarter of 2022
Time of Update: 2022-05-17
According to the classification of drug treatment categories, the drug categories with the largest number of new drug approvals are anti-tumor drugs, reproductive system drugs, sex hormones and skeletal and muscle drugs, with 13, 11 and 4 drugs respectively .
-
The head of Novartis Innovative Drugs China confirmed!
Time of Update: 2022-05-17
Novartis' business "two-in-one" innovative drug China head confirmed In the past two years, multinational pharmaceutical companies have set off a new round of organizational restructuring, with frequent personnel changes .
-
Three major varieties of CSPC Ouyi have been approved for production and are deemed to have been reviewed
Time of Update: 2022-05-17
On April 21, NMPA's official website showed that CSPC Ouyi Pharmaceutical's vortioxetine hydrobromide tablets, esomeprazole sodium for injection, and nifedipine controlled-release tablets were approved for production and deemed to have been reviewed.
-
Chia Tai Tianqing's onslaught of innovative drugs This year, 7 class 1 new drugs were approved for clinical use
Time of Update: 2022-05-17
On April 19, CDE's official website showed that Chia Tai Tianqing's Class 1 new drug TQH2722 injection was approved for clinical use and is intended to be used for the treatment of atopic dermatitis .
-
Once the bird flu strikes, it may exacerbate the supply of raw materials for anti-new crown traditional Chinese medicine!
Time of Update: 2022-05-17
Analysis of raw materials: the market will still run at a high level before the new production, and the market of some varieties will be adjusted after the new production Figure 7: From January 2019 to April 2022, the market changes of Cork, Gardenia, Banlangen, Rhubarb, and Scutellaria Scutellariae: Overall The annual consumption is maintained at around 10,000 tons.
-
"Recombinant Humanized Collagen" Medical Device Industry Standard Project Approval
Time of Update: 2022-05-17
On April 24, the General Department of the State Food and Drug Administration issued a notice on the establishment of the "Recombinant Humanized Collagen" medical device industry standard .
Attachment: Medical Device Industry Standard Formulation and Revision Project
